Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORE Zambia: RFDA vs RFTAT for Malaria Elimination
NCT02654912Phase 4Completed
- Sponsor
- PATH
- Start
- Feb 2016
- Primary completion
- Jun 2020
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dihydroartemisinin + piperaquine in malaria, sponsored by PATH. Started Feb 2016; status: completed.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02654912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654912.